» Articles » PMID: 24916103

EZH2 Represses Target Genes Through H3K27-dependent and H3K27-independent Mechanisms in Hepatocellular Carcinoma

Overview
Journal Mol Cancer Res
Specialty Cell Biology
Date 2014 Jun 12
PMID 24916103
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Alterations of polycomb group (PcG) genes directly modulate the trimethylation of histone H3 lysine 27 (H3K27me3) and may thus affect the epigenome of hepatocellular carcinoma (HCC), which is crucial for controlling the HCC cell phenotype. However, the extent of downstream regulation by PcGs in HCC is not well defined. Using cDNA microarray analysis, we found that the target gene network of PcGs contains well-established genes, such as cyclin-dependent kinase inhibitors (CDKN2A), and genes that were previously undescribed for their regulation by PcG, including E2F1, NOTCH2, and TP53. Using chromatin immunoprecipitation assays, we demonstrated that EZH2 occupancy coincides with H3K27me3 at E2F1 and NOTCH2 promoters. Interestingly, PcG repress the expression of the typical tumor suppressor TP53 in human HCC cells, and an increased level of PcG was correlated with the downregulation of TP53 in certain HCC specimens. Unexpectedly, we did not find obvious H3K27me3 modification or an EZH2 binding signal at the TP53 promoters, suggesting that PcG regulates TP53 expression in an H3K27me3-independent manner. Finally, the reduced expression of PcGs effectively blocked the aggressive signature of liver cancer cells in vitro and in vivo.

Implications: Taken together, our results establish the functional and mechanistic significance of certain gene regulatory networks that are regulated by PcGs in HCC.

Citing Articles

Alternative splicing of EZH2 regulated by SNRPB mediates hepatocellular carcinoma progression via BMP2 signaling pathway.

Wang X, Liu W, Zhan C, Zhang Y, Li X, Wang Y iScience. 2025; 28(1):111626.

PMID: 39850359 PMC: 11754826. DOI: 10.1016/j.isci.2024.111626.


EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2.

Lai Y, Han X, Xie B, Xu Y, Yang Z, Wang D Cancer Sci. 2024; 115(7):2220-2234.

PMID: 38623968 PMC: 11247551. DOI: 10.1111/cas.16186.


Insight into the Inhibitory Mechanism of Embryonic Ectoderm Development Subunit by Triazolopyrimidine Derivatives as Inhibitors through Molecular Dynamics Simulation.

Ju J, Zhang H, Guan S, Liu C, Du J, Shen X Molecules. 2023; 28(24).

PMID: 38138487 PMC: 10745707. DOI: 10.3390/molecules28247997.


Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability.

Amin M, El-Far Y, El-Mowafy M, Elgaml A Clin Epigenetics. 2023; 15(1):180.

PMID: 37941056 PMC: 10634085. DOI: 10.1186/s13148-023-01593-8.


WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.

Rialdi A, Duffy M, Scopton A, Fonseca F, Zhao J, Schwarz M Nat Cancer. 2023; 4(8):1157-1175.

PMID: 37537299 PMC: 10948969. DOI: 10.1038/s43018-023-00609-9.